Manulife (Manufacturers Life Insurance)’s Quince Therapeutics QNCX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-311	Closed	-$790	–	3166
2021 Q4	$790	Sell	311 -80	-20%	-$488K	﹤0.01%	1982
2021 Q3	$7.17M	Sell	391 -167	-30%	-$2.66M	0.01%	1094
2021 Q2	$5.91M	Buy	558 +11	+2%	+$92.2K	﹤0.01%	1202
2021 Q1	$3.94M	Sell	547 -2	-0.4%	-$14.4K	﹤0.01%	1354
2020 Q4	$3.05M	Buy	549 +2	+0.4%	+$17.7K	﹤0.01%	1395
2020 Q3	$5.47M	Sell	547 -1	-0.2%	-$9.1K	0.01%	1078
2020 Q2	$4.93M	Buy	548 +10	+2%	+$91.6K	﹤0.01%	1121
2020 Q1	$4.91M	Buy	538 +38	+8%	+$375K	0.01%	1029
2019 Q4	$5.61M	Hold	500	–	–	0.01%	1142
2019 Q3	$2.46M	Hold	500	–	–	﹤0.01%	1329
2019 Q2	$4.25M	Buy	+500	New	+$2.99M	0.01%	1226

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s QNCX Position: Q1 2022 in Review

Manulife (Manufacturers Life Insurance) sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 311 shares — an estimated $790 sold.

Manulife (Manufacturers Life Insurance) first reported a position in QNCX in Q2 2019 and held it in 11 quarters. The position peaked at $7.17M in Q3 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

Manulife (Manufacturers Life Insurance) reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
Manulife (Manufacturers Life Insurance) sold 311 Quince Therapeutics shares in Q1 2022, an estimated $790.
Manulife (Manufacturers Life Insurance) first reported a position in Quince Therapeutics in Q2 2019 and held it in 11 quarters.
Manulife (Manufacturers Life Insurance)'s Quince Therapeutics position peaked at $7.17M in Q3 2021.
85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2022, filed 20 May 2022.